NCT03363984

Pharmacokinetic Interaction Between Midazolam and ID-082 in Healthy Subjects

A Single-center, Open-label Study to Investigate the Effect of a Single Oral Dose and Repeated Oral Doses of ID-082 on the Pharmacokinetics of Midazolam and Its Metabolite 1-hydroxymidazolam in Healthy Male Subjects.

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Idorsia Pharmaceuticals Ltd. · Industry
• Sex: Male
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

A clinical study in healthy male subjects to investigate whether the administration of ID-082 can affect the fate in the body (amount and time of presence in the blood) of midazolam.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Midazolam	Single oral administration of 2 mg midazolam under fasted conditions/outside of meal times
DRUG	ID-082	Administration of ID-082 under fasted conditions/outside of meal times

Timeline

• Start date: 2017-11-27
• Primary completion: 2017-12-19
• Completion: 2017-12-19
• First posted: 2017-12-06
• Last updated: 2018-06-27

Locations

1 site across 1 country: United Kingdom